Comments on the Carcinogenic, Mutagenic, and Teratogenic Properties of Anticancer Drugs

  • F. M. Muggia
  • J. Ziegler
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 74)

Summary

Relevance of the carcinogenic effects of anticancer agents has arisen in the context of three circumstances: (a) when patients who have a favorable outlook without treatment receive chemotherapy, (b) when several alternate therapies with varying carcinogenic potential are available, and (c) when considering the introduction of a new drug into clinical investigation and/or clinical practice. Teratogenic effects require special attention when dealing with women in their reproductive years. Techniques to evaluate the mutagenic effects have opened up new areas of research and will be increasingly applied to the study of anticancer drugs.

Keywords

Lymphoma Radium Sarcoma Melphalan Myeloma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adamson RH, Krolikowski FJ, Correa P, Sieber SM, Dalgard DW (1977) Carcinogenicity of 1-methyl-l-nitrosourea in nonhuman primates. J Natl Cancer Inst 59:415–419Google Scholar
  2. 2.
    Adamson RH, Sieber SM (1977) Carcinogenic potential of cancer chemotherapy agents in man. Cancer Bull 29:179–183Google Scholar
  3. 3.
    Arsenau JC, Canellos GP, Johnson R, DeVita VT Jr (1977) Risks of new cancers in patients with Hodgkin’s disease. Cancer 40:1912–1916CrossRefGoogle Scholar
  4. 4.
    Coleman NC, Williams CJ, Flint A, Glatstein EJ, Rosenberg SA, Kaplan HS (1977) Hematologic neoplasia in patients treated for Hodgkin’s disease. N Engl J Med 297:1249–1257PubMedCrossRefGoogle Scholar
  5. 5.
    D’Angio GJ, Meadows AT, Mike V, Harris C, Evans A, Jaffe N, Newton W, Schweisguth O, Sutow W, Morris-Jones P (1976) Decreased risk of radiation-associated second malignant neoplasms in actinomycin-D-treated patients. Cancer 37:1177–1185PubMedCrossRefGoogle Scholar
  6. 6.
    Greene MH, Boice JD, Keehn RJ, Higgins GA, Fraumeni JF (1979) Late effects of low dose adjuvant chemotherapy in colorectal cancer. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:413Google Scholar
  7. 7.
    Li FP (1977) Second malignant tumors after cancer in childhood. Cancer 40:1899–1902PubMedCrossRefGoogle Scholar
  8. 8.
    Muggia F, Catane R, Lee YJ, Rozencweig M (1979) Factors responsible for therapeutic success in osteosarcoma: A critical analysis of adjuvant trial results. In: Salmon S, Jones SE (eds) Adjuvant therapy in man. Elsevier/North-Holland, Amsterdam, pp 383–390Google Scholar
  9. 9.
    Reimer RR, Hoover R, Fraumeni JF Jr, Young RC (1977) Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 297:177–181PubMedCrossRefGoogle Scholar
  10. 10.
    Rosner F (1976) Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 37:1033–1036PubMedCrossRefGoogle Scholar
  11. 11.
    Scott D, Bridges BA, Sobels FH (1977) Progress in genetic toxicology. Elsevier/North-Hol- land, AmsterdamGoogle Scholar
  12. 12.
    Sherins RJ, DeVita VT Jr (1973) Effect of drug treatment for lymphoma on male reproductive capacity. Ann Intern Med 79:216–220PubMedGoogle Scholar
  13. 13.
    Stribling J, Weitzner S, Smith GV (1978) Kaposi’s sarcoma in renal allograft recipient. Cancer 47:442–446CrossRefGoogle Scholar
  14. 14.
    Sugimura T, Matsushima T, Sawamura M, Seino Y, Yahagi T, Nagao M (1978) Predication of risk of a second tumor and use of the mutation test for monitoring improvement of drugs. In: Carter SK, Goldin A, Kuretani K, Mathe G, Sakurai Y, Tsukagoshi S, Umezawa H (eds) Advances in cancer chemotherapyGoogle Scholar
  15. 15.
    Valagussa P, Kenda R, Fossati Bellani F, Franchi F, Banfi A, Rilke F, Bonadonna G (1979) Incidence of second malignancies in Hodgkin’s disease (HD) after various forms of treatment. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:360Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • F. M. Muggia
  • J. Ziegler

There are no affiliations available

Personalised recommendations